- Home
- / 4D Molecular Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
4D Molecular Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$8.2
2024-10-29
Market Capitalization
$426.2 M
2024-10-29
Revenue
$85.2 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|
| Revenue | 3.1M | 20.7M | 37.0K | 85.2M |
| General and administrative expense | 32.9M | 36.5M | 46.6M | 49.1M |
| Operating expense total | 113.2M | 133.6M | 187.9M | 244.8M |
| EBIT | (110.0M) | (112.9M) | (187.8M) | (159.5M) |
| EBIT margin, % | -3516.5% | -544.6% | -507678.4% | -187.2% |
| Interest income | 2.6M | 12.2M | 27.1M | 19.5M |
| Net Income | (107.5M) | (100.8M) | (160.9M) | (140.1M) |
| EPS | (3.3) | (2.6) | (3.0) | (2.4) |